Clinical Trial Update: Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of ZK219477 for recurrent ovarian cancer has completed; Bayer is sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• ZK219477

Snippet

Sponsor: Bayer | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED